https://mail.asiapharmaceutics.info/index.php/ajp <p style="text-align: justify;"><strong>Asian Journal of Pharmaceutics</strong> is an international Referred and Peer Reviewed Online and print Journal with E-ISSN: <strong>1998-409X </strong>and P-ISSN: <strong>0973-8398 </strong>published by<strong> B R Nahata Smriti Sansthan </strong>for the enhancement of research and extension in Pharmaceutics. AJP is an open access online Journal, that publishes full-length papers, reviews and short communications exploring and to promote diverse and integrated areas of Pharmaceutics and Pharmaceutical Technology, Formulation Design and Development, Drug Discovery and Development Interface, Manufacturing Science and Engineering, Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Clinical Pharmacology, General Medicine and Translational Research, Physical Pharmacy and Biopharmaceutics, Novel Drug delivery system, Biotechnology &amp; Microbiological evaluations, Regulatory Sciences. AJP is steered by a distinguished Board of Editors. To maintain a high-quality journal, manuscripts that appear in the AJP Articles section have been subjected to a rigorous review process.</p> <p><strong><u>JOURNAL PARTICULARS</u></strong></p> <table> <tbody> <tr> <td width="281"> <p>Title</p> </td> <td width="517"> <p>Asian Journal of Pharmaceutics</p> </td> </tr> <tr> <td width="281"> <p>Frequency</p> </td> <td width="517"> <p>Quarterly</p> </td> </tr> <tr> <td width="281"> <p>E- ISSN</p> </td> <td width="517"> <p><strong>1998-409X</strong></p> </td> </tr> <tr> <td width="281"> <p>P-ISSN</p> </td> <td width="517"> <p><strong>0973-8398</strong></p> </td> </tr> <tr> <td width="281"> <p>DOI</p> </td> <td width="517"> <p><strong>https://doi.org/10.22377/ajp.v10i04</strong></p> </td> </tr> <tr> <td width="281"> <p>Publisher</p> </td> <td width="517"> <p><strong>Mr. Narendra Nahata</strong>, B.R. Nahata College of Pharmacy, Mhow-Neemuch Road, Mandsaur-458001, Madhya Pradesh</p> </td> </tr> <tr> <td width="281"> <p>Chief Editor</p> </td> <td width="517"> <p>Dr. M.A. Naidu</p> </td> </tr> <tr> <td width="281"> <p>Starting Year</p> </td> <td width="517"> <p>2007</p> </td> </tr> <tr> <td width="281"> <p>Subject</p> </td> <td width="517"> <p>Pharmacy subjects</p> </td> </tr> <tr> <td width="281"> <p>Language</p> </td> <td width="517"> <p>English Language</p> </td> </tr> <tr> <td width="281"> <p>Publication Format</p> </td> <td width="517"> <p>Online and Print [Both]</p> </td> </tr> <tr> <td width="281"> <p>Email Id</p> </td> <td width="517"> <p><a href="mailto:editor@asiapharmaceutics.info">editor@asiapharmaceutics.info</a>,editor@brnsspublicationhub.org</p> </td> </tr> <tr> <td width="281"> <p>Mobile No.</p> </td> <td width="517"> <p>+91-7049737901</p> </td> </tr> <tr> <td width="281"> <p>Website</p> </td> <td width="517"> <p>www.asiapharmaceutics.info</p> </td> </tr> <tr> <td width="281"> <p>Address</p> </td> <td width="517"> <p>B.R. Nahata Smriti Sansthan, BRNSS PUBLICATION HUB, B.R. Nahata College of Pharmacy, Mhow-Neemuch Road, Mandsaur-458001, Madhya Pradesh</p> </td> </tr> </tbody> </table> <p> </p> en-US <p>This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.</p> editor@asiapharmaceutics.info (M.A. Naidu) nilesh.jain@meu.edu.in (Dr. Nilesh Jain) Sat, 10 Jan 2026 14:30:11 +0000 OJS 3.3.0.10 http://blogs.law.harvard.edu/tech/rss 60 https://mail.asiapharmaceutics.info/index.php/ajp/article/view/7008 <p>Tuberculosis (TB) remains a major global health challenge, with limitations in the present drug regimens, including</p> <p>poor bioavailability, systemic side effects, and the emergence of multidrug resistance. Rifampicin (RMP), a firstline anti-TB drug, suffers from rapid metabolism, limited tissue penetration, and poor targeting, necessitating</p> <p>frequent dosing. Nanoparticle-based drug delivery systems offer a promising strategy to address these challenges</p> <p>by enhancing targeted delivery, reducing toxicity, and improving therapeutic efficacy. A disruptive solution</p> <p>to these challenges is presented by nanotechnology-based drug delivery systems. In this review, we examine</p> <p>various studies on RMP-loaded nanoparticles, including polymeric nanoparticles, lipid-based nanocarriers (such</p> <p>as liposomes and solid lipid nanoparticles), metallic nanoparticles, dendrimers, and micelles. These carriers</p> <p>enhance the stability of the drug, facilitate its controlled release, and target its delivery to TB-infected tissues and</p> <p>macrophages. Nanocarriers loaded with RMP have a high potential for transforming TB treatment because they</p> <p>are more effective, have fewer systemic adverse effects, and are part of combating TB drug resistance on a global</p> <p>scale.</p> Mohd Imran Copyright (c) 2026 Mohd Imran https://creativecommons.org/licenses/by-nc/4.0 https://mail.asiapharmaceutics.info/index.php/ajp/article/view/7008 Fri, 10 Jan 2025 00:00:00 +0000